• human papillomavirus infection;
  • cervical cancer, epidemiology;
  • China


  1. Top of page
  2. Abstract
  6. Acknowledgements

A large-scale epidemiologic survey on the prevalence of different types of human papillomavirus (HPV) in cervical cancer in China is indicated because of the implications for the development of diagnostic probes and vaccines against cervical cancer. A total of 809 cervical cancer specimens were collected from 5 regions in China including Shanghai, Guangzhou, Sichuan, Beijing and Hong Kong. HPV DNA was detected in 83.7% of the specimens. HPV-16 was present in 79.6%, HPV-18 in 7.5%, HPV-52 in 2.6% and HPV-58 in 3.8% of all HPV-positive specimens. The prevalences of HPV-16 and HPV-18 in Hong Kong were 61.7 and 14.8%, respectively, representing a lower HPV-16 and a higher HPV-18 proportion compared with the other regions. HPV-16 remained the most common HPV infection in both squamous cell carcinoma (SCC) and adenocarcinoma (AC). The proportion of HPV-18 infection was significantly higher in AC than in SCC. © 2002 Wiley-Liss, Inc.

There is strong epidemiologic evidence indicating that human papillomavirus (HPV) plays a central role in the etiology of cervical cancer.1, 2, 3, 4 The women positive for HPV DNA have a risk of developing cervical cancer 15–50 times higher than those without HPV DNA.1, 2, 4, 5 Although HPV infection is common among young women, only a small minority go on to develop cervical cancer. This situation was reviewed by a group of researchers, who concluded that viral persistence of oncogenic HPV appears to be crucial for the development of cervical cancer.6 Indeed, HPV-16, -18, -31 and -33 have been officially declared to be oncogenic by the World Health Organization (WHO).7

The International Biological Study on Cervical Cancer (IBSCC) study group revealed that on average 92.9% of the tumors contained HPV DNA, with a range of 75–100%.8 Although this international survey included 10 of the 18 regions of the world and provided the most extensive global view of HPV in cervical cancer, there were no data from China, 1 of the largest populations in the world. Furthermore, there are few published data from a well-designed study using a quality-controlled method on the prevalence of either HPV infection or HPV genotypes in cervical cancers in China.

We conducted a multicenter study of HPV infection in cervical cancer by selecting 5 geographic regions of China: Shanghai (Eastern China), Guangzhou (Southern China), Sichuan (Western China), Beijing (Northern China) and Hong Kong (Specific Administration Region).


  1. Top of page
  2. Abstract
  6. Acknowledgements


Cervical cancer specimens were collected from each of the 5 regions in China, including Shanghai, Guangzhou, Sichuan, Beijing and Hong Kong. Each of the 5 settings (Tumor Hospital, Shanghai Medical University in Shanghai, Tumor Hospital, Sun Yat-sen University of Medical Sciences in Guangzhou, Second Hospital, West China Medical University in Sichuan, Tumor Hospital, Chinese Academy of Medical Sciences in Beijing, and Prince of Wales Hospital, The Chinese University of Hong Kong in Hong Kong) was responsible for collecting 150 or more tumor specimens consecutively from the year 1997 to 1999. Patients from Hong Kong were prospectively recruited with informed consent, and all specimens were freshly frozen. Those specimens collected in other parts of China were paraffin-embedded and retrieved retrospectively from the pathology files in those reference centers. Ethical approvals were obtained from each of the ethical review boards of the respective institutes.

Histology Review

All histologic slides submitted were reviewed by 1 of the investigators (M.K.M.C.) to reestablish the histologic type and grade of differentiation according to the criteria of the WHO. Equivocal and unusual specimens were examined jointly with a second investigator (Y.F.W.).

Preparation of DNA

DNA from paraffin-embedded tissue sections was extracted as previously described.9 Briefly, 5–15 10 μm thick sections were deparaffinized with organic solvents, and high molecular weight DNA was prepared from tumor specimens by proteinase K digestion and phenol/chloroform extraction. Microdissection was performed to enrich the tumor cells if the proportion of cancer cells in tissue section was less than 50%. Procedures to prevent specimen contamination and PCR carryover were observed at every step.10, 11 Specimens from Hong Kong were freshly frozen and confirmed histologically to contain no less than 50% tumor cells. Tumor tissue was also digested by proteinase K, and DNA was isolated after phenol/chloroform extraction and ethanol precipitation.

Detection and Typing of HPV

All HPV assays were done at the Gynecologic Cancer Research Laboratory, The Chinese University of Hong Kong. The following steps were used to ensure the highest probability of detecting HPV DNA (Fig. 1).

thumbnail image

Figure 1. Flow chart illustrating the steps in human papillomavirus (HPV) DNA detection. RFLP, restriction fragment length polymorphism.

Download figure to PowerPoint

Step 1.

Use of a pair of degenerate MY09/11 consensus primers in the highly conserved L1 open reading frame of HPV yielded a 450 bp fragment.12 The PCR conditions were optimized. In brief, a 50 μl amplification mixture consisted of 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 100 μM of each dNTP, 0.25 μM of each primer, 2 units of Taq polymerase (GIBCO BRL, Life Technologies, Paisley, Scotland) and 1 μl of cervical cancer sample DNA (containing about 25 ng of DNA). Thirty-five cycles of amplification were carried out as follows: denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for 1 min. The initial denaturation was for 3 min at 94°C, and the final elongation step was extended to 10 min. The products of the reaction were electrophoresed on 2% agarose gel. The positive PCR products were subjected to direct DNA sequencing for HPV genotyping.

Step 2.

The integrity of DNA in negative specimens tested by PCR using the MY09/11 consensus primer was examined by a β-actin PCR assay, yielding a human β-actin product of 303 bp using a primer pair of 5′-GAAACTACCTTCAACTCCATC-3′ and 5′-CTAGAAGCATTTGCGGTGGACGATGGAGGGGCC-3′. This was also used to confirm that nonspecific inhibitors were absent.

Step 3.

Negative specimens of the β-actin PCR assay were excluded from the study, and positive specimens were further screened for HPV infection using HPV-16, -18, -31, -33, -52 and -58 specific PCR. For PCRs of HPV-16, -18, -31 and -33, we adopted the methods previously described by Baay and colleagues;13 for PCRs of HPV-52 and -58, we used the primer pair: 5′-GCATTCATAGCACTGCCAC-3′; and 5′-GCCTCTACTTCAAACCAGCC-3′, corresponding to positions of the sense strand 761–779 and antisense strand 909–928 and yielding a 168 bp amplimer, as well as the primer pair: 5′-CATGTACCATTGTGTGCCC-3′ and 5′-ACCGCTTCTACCTCAAACC-3′, resulting in a 118 bp amplimer corresponding to positions of the sense strand 833–851 and antisense strand 932–950, yielding a 118–bp amplimer. A 50 μl amplification mixture consisted of 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 100 μM of each dNTP, 0.25 μM of each primer, 2 units of Taq polymerase (GIBCO BRL, Life Technologies) and 1 μl of cervical cancer sample DNA. Thirty-five cycles of amplification were carried out as follows: denaturation at 94°C for 30 sec, annealing at 59°C for 30 sec and extension at 72°C for 1 min. The initial denaturation was 3 min at 94°C, and the final elongation step was extended to 10 min.

Step 4.

In negative specimens tested by the 6 genotypes of HPV type-specific PCR described above, HPV DNA was further examined by PCR using another pair of consensus primers, GP5+/6+, from the HPV L1 region, yielding a 110 bp fragment.14

Step 5.

The positive specimens found by using GP5+/6+ PCR were subjected to direct DNA sequencing again. If the direct sequencing was unsuccessful, the specimens were defined as unknown type HPV infection. Nevertheless, the negative specimens by GP5+/6+ PCR were defined as HPV infection negative.

Step 6.

In specimens in which direct DNA sequencing failed after the detection of HPV infection positivity by MY09/11 PCR, HPV typing using restriction fragment length polymorphism (RFLP) was performed.15 If the HPV typing was still unsuccessful, then steps 3–5 were repeated. Each PCR included a positive and negative control. Purified DNA obtained from plasmids or known type-specific positive cervical cancer DNA samples was used as positive controls, and HPV-negative DNA was from the K-562 cell line.

Statistical Methods

Log-linear models were fitted to the contingency table cross-classified by 4 factors: geographic regions, HPV type, histology and grade. The adequacy of the independence model was first addressed by a likelihood ratio test. The highest order of associations to be included in the model was also found. Finally, a parsimonious model was constructed by using backward elimination. Goodness-of-fit of the final model was assessed by the likelihood ratio test. Chi-squared tests were used to detect any geographic differences in HPV prevalence, geographic differences in cell differentiation and differences in prevalence of HPV types by histologic type. Two-sided p-values were calculated, and p < 0.05 was considered significant to take into account the multiple comparisons. Statistical analysis was performed using the Statistical Analysis System software package (SPSS 10.0, SPSS, Chicago, IL).


  1. Top of page
  2. Abstract
  6. Acknowledgements

After exclusion of 54 cases with no detectable DNA (cases with negative β-actin PCR) of which 33 cases were from Shanghai, 20 from Sichuan and 1 from Beijing, a total of 809 cervical cancer specimens were collected from the 5 regions of China (Table I). The diagnosis of invasive cervical carcinoma was confirmed in all specimens, which consisted of 731 (90.4%) squamous cell carcinomas (SCCs), 74 (9.1%) adenocarcinomas (ACs) and 4 (0.5%) adenosquamous carcinomas (ASs). Based on the degree of nuclear and architectural abnormality and the proportion of cells exhibiting cytoplasmic differentiation, tumors were graded as well differentiated in 145 (17.9%), moderately differentiated in 427 (52.8%) and poorly differentiated in 237 (29.3%) cases.

Table I. HPV Prevalence by Geographic Regions Studied1
Geographic regionHPV, case nos. (% within regions)Total
  • 1

    HPV, human papillomavirus.

Shanghai32 (21.3)118 (78.7)150 (100.0)
Guangzhou19 (12.6)132 (87.4)151 (100.0)
Sichuan20 (12.3)143 (87.7)163 (100.0)
Beijing28 (18.7)122 (81.3)150 (100.0)
Hong Kong33 (16.9)162 (83.1)195 (100.0)
Total132 (16.3)677 (83.7)809 (100.0)

HPV DNA was detected in 677 (83.7%) of 809 specimens (Table I). The prevalence varied between 78.7% from Shanghai to 87.7% from Sichuan (p value for heterogeneity = 0.14). HPV-16 was present in 79.6% (n = 541), HPV-18 in 7.5% (n = 51), HPV-31 in 0.7% (n = 5), HPV-33 in 1.8% (n = 12), HPV-45 in 0.4% (n = 3), HPV-52 in 2.6% (n = 18) and HPV-58 in 3.8% (n = 26) of all HPV-positive specimens (n = 680, double-counted in 3 cases with double infection; Table II).Twenty-three (3.4%, 95% confidence interval [CI] = 2.3–5.2%) HPV-positive specimens harbored HPVs that could not be typed. Double infection occurred in 3 (0.8%, 95% CI = 0.2–2.2%) of 381 HPV-positive cases in which HPV DNA was not typed by direct DNA sequencing. The other 296 cases using direct sequencing were excluded from the calculation, as the process of HPV detection was stopped after 1 HPV type was found. Each of them consisted of 2 different viruses, namely, HPV-18 and -58; HPV-18 and -31; and HPV-18 and -52. HPV-16 and -18 remained the most frequently encountered and added up to a total of 87.1%. HPV-58 and -52 were found to be the third (3.8%) and fourth (2.6%) most common genotypes in our study population.

Table II. HPV Type by Geographic Region Studied1
HPV typesGeographic regions, case nos. (% within regions)
ShanghaiGuangzhouSichuanBeijingHong KongTotal
  • 1

    HPV, human papillomavirus. p-value for heterogeneity of HPV type among the geographic regions = 0.14.

  • 2

    Three cases with mixed infection were double-counted.

HPV-16106 (89.0)100 (75.2)123 (85.4)112 (91.8)100 (61.7)541 (79.6)
HPV-183 (2.5)8 (6.0)12 (8.3)4 (3.3)24 (14.8)51 (7.5)
HPV-521 (0.9)5 (3.8)2 (1.4)2 (1.6)8 (5.0)18 (2.6)
HPV-583 (2.5)6 (4.5)3 (2.1)3 (2.5)11 (6.8)26 (3.8)
Others6 (5.1)14 (10.5)4 (2.8)1 (0.8)19 (11.7)44 (6.5)
Total1192 (100.0)1332 (100.0)1442 (100.0)122 (100.0)162 (100.0)6802 (100.0)

The associations among geographic region, HPV type, histologic type and grade of differentiation were explored using log-linear models. The highest order of association was found to be 2. The resulting log-linear model indicated that there were significant associations (p < 0.0005) between geographic regions and HPV types (Table II), geographic regions and grade of differentiation (Table III) and HPV type and histologic type (Table IV). The likelihood ratio test showed no evidence of poor fit to the data (p = 0.923).

Table III. Grade of Differentiation by Geographic Region Studied
Grade of differentiationGeographic regions, case nos. (% within regions)
ShanghaiGuangzhouSichuanBeijingHong KongTotal
Well25 (21.2)18 (13.6)19 (13.3)26 (21.3)37 (22.8)125 (18.5)
Moderate60 (50.8)50 (37.9)74 (51.7)83 (68.0)89 (54.9)356 (52.6)
Poor33 (28.0)64 (48.5)50 (35.0)13 (10.7)36 (22.2)196 (28.9)
Total118 (100.0)132 (100.0)143 (100.0)122 (100.0)162 (100.0)677 (100.0)
Table IV. HPV Type by Histologic Type Studied1
HPV typeHistologic types, case nos. (% within histologic types)
  • 1

    HPV, human papillomavirus; SCC, squamous cell carcinoma; AC, adenocarcinoma; AS, Adenosquamous carcinoma.

  • 2

    Three cases with mixed infection were double-counted.

HPV-16505 (81.0)34 (64.2)2 (50.0)541 (79.6)
HPV-1834 (5.5)15 (28.3)2 (50.0)51 (7.5)
HPV-5216 (2.6)2 (3.8)0 (0)18 (2.6)
HPV-5825 (4.0)1 (1.9)0 (0)26 (3.8)
Others43 (6.9)1 (1.9)0 (0)44 (6.5)
Total6232 (100.0)53 (100.0)4 (100.0)6802 (100.0)

The prevalence of HPV-58 and -52 was higher in southern regions (Guangzhou and Hong Kong) compared with the rest (Shanghai, Sichuan and Beijing) of China (HPV-52, 13/295 vs. 5/385, 4.4% vs. 1.3%, p = 0.02 and HPV 58, 17/295 vs. 9/385, 5.8% vs. 2.3%, p = 0.03). The prevalence rates of HPV-16 and -18 in Hong Kong were 61.7 and 14.8%, respectively, representing a lower HPV-16 (100/162 vs. 441/518, 61.7% vs. 85.1%, p < 0.00005) and a higher HPV-18 (24/162 vs. 27/518, 14.8% vs. 5.2%, p = 0.0001) proportion compared with the other regions (Table II). Among the HPV-positive cervical tumors, they were graded as well differentiated in 125 (18.5%), moderately differentiated in 356 (52.6%) and poorly differentiated in 196 (28.9%) cases (Table III). The proportion of poorly differentiated tumors was higher in Guangzhou (64/132 vs. 132/545, 48.5% vs. 24.2%, p < 0.00005) and lower in Beijing (13/122 vs. 183/555, 10.7% vs. 33.0%, p < 0.00005) compared with other regions. Among the HPV-positive cervical tumors, 623 (91.6%) were SCCs, 53 (7.8%) were ACs and 4 (0.6%) were ASs (Table IV). HPV-16 and -18 remained the most common HPV infection in both SCC and AC. The proportion of HPV-18 infection was significantly higher in AC than in SCC (15/53 vs. 34/623, 28.3% vs. 5.5%, p < 0.00005). There was no significant variation in types of HPV infection among different tumor grade (Table V).

Table V. HPV Type by Grade of Differentiation Studied
HPV typeGrade of differentiation, case nos. (% within grade of differentiation)
  • 1HPV, Human papillomavirus; SCC, squamous cell carcinoma; AC, adenocarcinoma; AS, Adenosquamous carcinoma.

  • 2

    Three cases with mixed infection were double-counted.

HPV-16103 (81.7)291 (81.3)147 (75.0)541 (79.6)
HPV-189 (7.1)26 (7.3)16 (8.2)51 (7.5)
HPV-520 (0)14 (3.9)4 (2.0)18 (2.6)
HPV-587 (5.6)8 (2.2)11 (5.6)26 (3.8)
Others7 (5.6)19 (5.3)18 (9.2)44 (6.5)
Total1262 (100)3582 (100)196 (100)6802 (100.0)


  1. Top of page
  2. Abstract
  6. Acknowledgements

The prevalence of HPV DNA is highly dependent on the detection method used. With sensitive PCR methods, detection of HPV genotypes in clinical specimens is usually achievable.16 These methods are capable of detecting HPV DNA at the single copy level even in an overwhelming background of human DNA. As the techniques of detecting viral DNA have improved, the reported prevalence among cervical cancer patients has increased dramatically in last decade.6, 17 The IBSCC study group revealed that on average, 92.9% of the tumors (range, 75–100%) contained HPV DNA.8 A recent reanalysis of those HPV-negative tumors, which included stringent control of histology and additional PCR-based assays, indicated that HPV is present in 99.7% of these cases,18 suggesting that HPV prevalence was previously underestimated.

In our series, we found that HPV DNA was present in 83.7% of cervical cancers of a Chinese population, similar to our previous results, which were confined to Hong Kong specimens collected before the year 1997.19 Whether this represents a true geographic variation or a detection problem is unclear. To minimize false-negative results, we centralized HPV detection in 1 research laboratory, and histologic review was conducted by 1 pathologist. We accepted an HPV-negative result only after microdissection of specimens to enrich the proportion of tumor cells.

Studies have shown that the overall prevalence of HPV is underestimated when a single method is used.13, 20 Various detection methods work in different ways and at different sites. The general consensus primers MY09/11 and GP5+/6+ target the L1 gene of the HPV genome, whereas type-specific primers target the E6 or E7 regions. Therefore, in addition to the most commonly used consensus primer MY09/11, 3 other detection methods were used in our study to ensure the highest possible detection of HPV DNA.

Among the 5 regions studied, there was no significant difference in geographic variation except in Hong Kong. HPV-16 and -18 contributed an average of 85 and 5%, respectively in the other 4 regions. However, we found HPV DNA in 83.1% patients in Hong Kong, including HPV-16 in 61.7% and HPV-18 in 14.8% patients and this was consistent with our previous result.19 The results in Hong Kong were similar to the worldwide figures reported by IBSCC study group:8: HPV-16 was by far the most frequently found virus genotype and accounted for 50–60% of all positive cases, with HPV-18 accounting for 10–20%. This may be a reflection of the fact that Hong Kong is the most international city of China and as such may have been exposed to the same worldwide viruses.

HPV-58 and -52 were found to be the third and fourth most common genotypes in our study; they are relatively uncommon in cervical cancers in the Americas, Europe, Africa and Southeast Asia.8 Their prevalence was higher in Guangzhou and Hong Kong. This is consistent with previous small studies indicating that HPV-58 and -52 were relatively more prevalent among Chinese populations in Taiwan and Shanghai.21, 22 HPV-58 and -52 were shown to be closely related to and grouped together with HPV-16, -31, -33, -35 and -67 under the same branch of an HPV phylogenetic tree, indicating similarities in their pathogenic potential.23 According to the multinational case-control study conducted by Munoz et al.,24 HPV-16 had an odds ratio (OR) for cervical cancer of 182 compared with controls. HPV-58 and -52 have ORs of 79 and 146, respectively.24 Our findings suggest that HPV-58 and -52 may also play a significant role in the etiology of cervical cancer.

We found mixed infections in only 0.8% of cases. This is lower than the rate of 4% detected in the worldwide study. As there is almost no cross-reactivity between the various genotypes, the development of vaccines and diagnostic probes may have to be genotype-specific. The finding of low prevalence of mixed infections may have some implications for both screening with combination genotype-specific diagnostic HPV probes and polyvalent vaccination program development. However, current detection methods were not optimized for the detection of double-positives.

Current data regarding the relationship between HPV-18 and histologic type are in line with those reported by others.25, 26 Although HPV-16 remained the most common HPV infection in both SCC and AC, our data demonstrate that HPV-18 has a significant association with AC. This finding may reflect the fact that different virus receptors exist in cervical cells with different morphologic potentials, or it may indicate that specific HPV infection actually plays a role in directing carcinogenesis.

The mainstay of cervical cancer prevention at present is cytologic screening. However, vaccination against HPV infections that are known to be oncogenic appears to be a viable option, although its efficacy remains to be explored in a large population. Vaccination against HPV may be particularly useful in Mainland China, where it is proving difficult to implement effective screening programs in this huge population. This is particularly so in the rural areas where most of the population lives. Vaccination may be more cost-effective in the longer term compared with the screening performed at present. However, screening, eventually at longer intervals, will remain necessary to detect those patients who do not respond to vaccination, those HPV infections caused by types not covered by available vaccines and HPV-negative cases.

There is ongoing research into the possibility of vaccination against HPV type-specific infection in the future27 and also into immunotherapeutic approachs toward disease control.28, 29 Knowledge of the HPV types that are commonly associated with cervical cancers in China allows more precise selection of HPV vaccine development. Such study is crucial for informing policy decisions pertinent to the development of genotype-specific HPV diagnostic probes for and vaccination strategies against HPV infection in Mainland China.


  1. Top of page
  2. Abstract
  6. Acknowledgements

Profs. H. zur Hausen and E.-M. de Villiers at the German Cancer Research Institute in Heidelberg gave valuable advice to ensure optimization and validation of the methodology of our study. We are also grateful to Prof. W.D. Lancaster, Geogetown University Medical Center, Washington, DC, and Prof. T. Matsukura for kindly providing HPV-52 and -58 plasmids, respectively. We thank the Gynecologic Cancer Research Laboratory and Lee Hysan Clinical Research Laboratories, The Chinese University of Hong Kong, for providing reagents and equipment.


  1. Top of page
  2. Abstract
  6. Acknowledgements
  • 1
    Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, Viladiu P, Navarro C, Martos C, Ascunce N. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52: 7439.
  • 2
    Bosch FX, Munoz N, de Sanjose S, Navarro C, Moreo P, Ascunce N, Gonzalez LC, Tafur L, Gili M, Larranaga I. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2: 41522.
  • 3
    Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85: 95864.
  • 4
    Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ, Walboomers JM. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69: 1149.
  • 5
    Peng H, Liu S, Mann V, Rohan T, Rawls W. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer 1991;47: 7116.
  • 6
    International Agency for Research on Cancer (IARC) working group. IARC Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. Vol. 64. Lyon: IARC, 1995.
  • 7
    Mayor S. Human papillomavirus classified as carcinogenic. BMJ 1996;313: 70.
  • 8
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87: 796802.
  • 9
    Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: InnisMA, WhiteT, SninskyJJ, eds. Polymerase chain reaction protocols: a guide to methods and application. San Diego: Academic Press, 1990. 1538.
  • 10
    Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339: 2378.
  • 11
    Kwok S. Procedures to minimize PCR-related product carry-over. In: InnisMA, WhiteT, SninskyJJ, eds. Polymerase chain reaction protocols. A guide to methods and applications. San Diego, Academic Press, 1990: 142–5.
  • 12
    Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990;82: 147784.
  • 13
    Baay MF, Quint WGV, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996: 7457.
  • 14
    Van den Brule AJ, Snijders PJ, Gordijn RL, Bleker OP, Meijer CJ, Walboomers JM. General primer-mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas. Int J Cancer 1990;45: 6449.
  • 15
    Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999;59: 2328.
  • 16
    Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7: 20914.
  • 17
    zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184: 913.
  • 18
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189: 129.
  • 19
    Lo KW, Cheung TH, Chung TK, Wang VW, Poon JS, Lam P, Wong YF. Clinical and prognostic significance of human papillomavirus in a Chinese population of cervical cancers. Gynecol Obstet Invest 2001;51: 2027.
  • 20
    Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johannsson B, Hagmar B. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34: 2095100.
  • 21
    Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY, Greer CE, You SL, Huang TW, Wu TC. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 1995;62: 56571.
  • 22
    Huang S, Afonina I, Miller BA, Beckmann AM. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 1997;70: 40811.
  • 23
    Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170: 107785.
  • 24
    Munoz N, Bosch X, Chichareon S, Eluf-Neto J, Ngelangel C, Caceres E, Rolon PA, Bayo S, Chaoukin N, Shah KV, Walboomers JM, Meijer CJ. A multinational case-control study on the risk of cervical cancer linked to 25 HPV types: which are the high-risk types? 18th HPV Conference, Barcelona 23–-28 July 2000. p 125.
  • 25
    Walker J, Bloss JD, Liao SY, Berman M, Bergen S, Wilczynski SP. Human papillomavirus genotype as a prognostic indicator in carcinoma of the uterine cervix. Obstet Gynecol 1989;74: 7815.
  • 26
    Nakagawa S, Yoshikawa H, Onda T, Kawana T, Iwamoto A, Taketani Y. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 1996;78: 193541.
  • 27
    Im SS, Monk BJ, Villarrealk LP. Prevention of cervical cancer with vaccines. Curr Oncol Rep 2001;3: 3228.
  • 28
    Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Kolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14: 148594.
  • 29
    Gissmann L, Osen W, Muller M, Jochmus I. Therapeutic vaccines for human papillomavirus. Intervirology 2001;44: 16775.